Literature DB >> 19303503

The role of procoagulants and anticoagulants in the development of venous thromboembolism.

Rogier M Bertina1.   

Abstract

Procoagulant and anticoagulant reactions play an important role in the regulation of thrombin formation during secondary hemostasis. Three phases can be recognized in the kinetics of thrombin formation: an initiation phase, a propagation phase and a termination phase. Dysregulation of thrombin formation during each of these phases by (hereditary) changes in the plasma concentration of pro- and anticoagulants contributes to the development of venous thrombosis. Most important seems the defective down-regulation of the prothrombinase activity during the termination phase. Procoagulant and anticoagulant proteins have important roles in the regulation of fibrin formation during secondary hemostasis. Under normal physiological conditions there is a delicate balance between the procoagulant and anticoagulant reactions. After damage to the vessel wall sufficient fibrin is formed to arrest bleeding and allow repair of the lesion without obstructing blood circulation. Venous thrombosis can be considered as a hemostatic process getting out of control, where massive fibrin formation has resulted in the formation of an obstructive thrombus. Such thrombus formation is believed to be facilitated by changes in the vessel wall, blood flow and the composition of the blood. During the past 50 years substantial progress has been made in our understanding of the enzymatic reactions involved in the hemostatic process. At the same time information has been obtained on particular changes in the composition of the blood which contribute to the development of venous thrombosis. Most of these changes concern the procoagulant and anticoagulant systems. In this paper I will briefly discuss how fibrin formation is regulated by procoagulant and anticoagulant reactions and how certain changes in these pathways contribute to the development of venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303503     DOI: 10.1016/S0049-3848(09)70142-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

Review 2.  Pathogenesis of thrombosis: cellular and pharmacogenetic contributions.

Authors:  Dileep D Monie; Emma P DeLoughery
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 3.  Are MPNs vascular diseases?

Authors:  Guido Finazzi; Valerio De Stefano; Tiziano Barbui
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

4.  Weight Change and Risk of Venous Thromboembolism: The Tromsø Study.

Authors:  Lars Daae Horvei; Sigrid K Brækkan; John-Bjarne Hansen
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

5.  The influence of corn trypsin inhibitor on the contribution of coagulation determinants to the Technoclone Thrombin Generation Assay (TGA) and the Calibrated Automated Thrombogram (CAT).

Authors:  Carolina E Touw; Ype de Jong; Astrid van Hylckama Vlieg
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

6.  Genetic predictors of fibrin D-dimer levels in healthy adults.

Authors:  Nicholas L Smith; Jennifer E Huffman; David P Strachan; Jie Huang; Abbas Dehghan; Stella Trompet; Lorna M Lopez; So-Youn Shin; Jens Baumert; Veronique Vitart; Joshua C Bis; Sarah H Wild; Ann Rumley; Qiong Yang; Andre G Uitterlinden; David J Stott; Gail Davies; Angela M Carter; Barbara Thorand; Ozren Polašek; Barbara McKnight; Harry Campbell; Alicja R Rudnicka; Ming-Huei Chen; Brendan M Buckley; Sarah E Harris; Annette Peters; Drazen Pulanic; Thomas Lumley; Anton J M de Craen; David C Liewald; Christian Gieger; Susan Campbell; Ian Ford; Alan J Gow; Michelle Luciano; David J Porteous; Xiuqing Guo; Naveed Sattar; Albert Tenesa; Mary Cushman; P Eline Slagboom; Peter M Visscher; Tim D Spector; Thomas Illig; Igor Rudan; Edwin G Bovill; Alan F Wright; Wendy L McArdle; Geoffrey Tofler; Albert Hofman; Rudi G J Westendorp; John M Starr; Peter J Grant; Mahir Karakas; Nicholas D Hastie; Bruce M Psaty; James F Wilson; Gordon D O Lowe; Christopher J O'Donnell; Jacqueline C M Witteman; J Wouter Jukema; Ian J Deary; Nicole Soranzo; Wolfgang Koenig; Caroline Hayward
Journal:  Circulation       Date:  2011-04-18       Impact factor: 29.690

7.  Antiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits.

Authors:  Yi Wang; Jie Wang; Liping Guo; Xiumei Gao
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-27       Impact factor: 2.629

8.  Indoor nanoscale particulate matter-induced coagulation abnormality based on a human 3D microvascular model on a microfluidic chip.

Authors:  Yan Li; Chuanlin Hu; Pengcheng Wang; Yan Liu; Luyang Wang; Qingmeng Pi; Zhiyong Gong; Xu Yang; Michael Mak; Yang Wu
Journal:  J Nanobiotechnology       Date:  2019-02-01       Impact factor: 10.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.